News
Sensorion Announces Initiation of Coverage by US Investment Bank Chardan with a “Buy” Recommendation
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Mobility: MND is awarded the construction of the 2nd urban ropeway line in Saint-Denis on Reunion Island
CINOR (Communauté intercommunale du Nord de La Réunion) has awarded the French ropeway manufacturer MND — representing the Payenke1 joint venture of six companies — a contract to design, build, and
VALBIOTIS wurde ausgewählt, auf den 80. wissenschaftlichen Sitzungen der American Diabetes Association die klinischen Phase-II-Ergebnisse zu TOTUM-63 bei Prädiabetes vorzustellen
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL / PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung
VALBIOTIS Selected at the 80th Scientific Sessions of the American Diabetes Association to Present Phase II Clinical Results of TOTUM-63 in Prediabetes
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces
Sensorion Announces Positive Preliminary Preclinical Data From Its Otoferlin Gene Therapy Program
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
AGROGENERATION : General Meeting to be held behind closed doors on June 26, 2020
Paris, June 5, 2020
Amid the ongoing COVID-19 epidemic and in line with government measures to slow the spread of the virus, the Company's General Meeting will be held on June 26, 2020 behind closed
Sensorion to attend Citi European Healthcare Conference
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent
DIETSWELL : 2019 Results
PRESS RELEASE Paris, May 27, 2020
2019 Results
- Results marked by a stalled oil market and high investments in TrussFloat
- Decrease in total revenue mitigated by Factorig's
Mauna Kea Technologies: Cellvizio® Endorsed By the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) as a Safe and Effective Diagnostic Tool
Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE)
Sensorion Publishes Results of General Assembly Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the
NEOVACS SHARES TO RESUME TRADING ON MAY 20TH, 2020
Paris and Boston, May 19th, 2020 5:30 PM CET - Néovacs (Euronext Growth Paris: ALNEV) confirms that it has requested the resumption of trading in its shares on Euronext as soon as possible in
NEOVACS : VALIDATION OF THE "RESTARTED" PLAN BY THE PARIS COMMERCIAL COURT
- End of court-ordered receivership proceedings
- Continuation of core research in lupus and allergies
- Creation of a new business investing in BioTechs and MedTechs
- New shareholder (HBR Investment
PRISMAFLEX INTERNATIONAL : 2019-2020 total sales: EUR 51.2 million (+5.2%)
Growth offset in Q4 by the Covid-19 crisis
Significant points 2019-2020
- Printing activity is solid for the period with overall growth at +4% despite a sharp drop in sales in March
- Hardware
NEOVACS : DRAFT CONTINUITY PLAN // REVIEW HEARING SCHEDULED FOR MAY 6th, 2020
Paris and Boston, May 4th, 2020 – 18.00 CET - Néovacs (Euronext Growth Paris: ALNEV) today provides an update on the ongoing insolvency proceedings.
The Paris Commercial Court will review the sole
Median Technologies: Liquidity Contract Transfer to Louis Capital Markets
Regulatory News:
Median Technologies (Paris:ALMDT) is announcing that on March 30, 2020, it concluded a new liquidity contract with the Company Louis Capital Markets in accordance with the Amafi
Sensorion Announces It Will Hold Its General Assembly on May 20, 2020 Behind Closed Doors Alongside the Publication of Its 2019 Annual Financial Report
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company that specializes in the development of novel therapies to restore, treat and prevent
Median Technologies Records Its Best Quarterly Performance and Joins Forces With Biopharmaceutical Companies in the Fight Against Covid-19
Regulatory News:
Median Technologies (Paris:ALMDT) (ALMDT), The Imaging Phenomics Company®, provides an update on its performance for Q1 2020 and a review of its commitment to tackle Covid-19.
EOS imaging Reports Its Full Year 2019 Results and First Quarter 2020 Revenues
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
Alphatec Holdings Terminates Tender Offer Agreement with EOS imaging
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME) ("EOS"), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical
Sensorion reschedules General Assembly to May 20
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the
VALBIOTIS veröffentlicht Jahresergebnisse für 2019
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung
VALBIOTIS publishes its annual results for 2019
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200420005808/en/
Valbiotis pipeline (Photo: Business Wire)
VALBIOTI
Median Technologies Receives a Disbursement of €15 Million, Corresponding to the First Tranche of the Loan Granted by the European Investment Bank
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200420005408/en/
Median Technologies (Paris:ALMDT), The Imaging
VALBIOTIS beschleunigt seine klinische Pipeline-Entwicklung im Hinblick auf neue Indikationen: Reduzierung von kardiovaskulären und Lebersteatose-Risiken
VALBIOTIS (Paris: ALVAL) (FR0013254851 – ALVAL / PEA/-KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Prävention und Bekämpfung von
VALBIOTIS Accelerates Its Pipeline Clinical Development in New Indications: Cardiovascular and Hepatic Steatosis Risk Reduction
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200415005751/en/
An advanced pipeline of active substances (Graphic